Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy R Sterling

Showing results (71-80 of 330) with videos related to

Pageof 33
Sort By:
Plos One|April 6, 2016
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, PeruLeonela Villegas, Larissa Otero, Timothy R Sterling, et al.
The Journal of Infectious Diseases|January 6, 2007
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapyTodd Hulgan, Bryan E Shepherd, Stephen P Raffanti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
From Exposure to Disease: Predicting Tuberculosis ProgressionMariana Araújo-Pereira, Rajita Bhavaraju, Mark Hatherill, et al.
Plos One|October 3, 2012
Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in careVlada V Melekhin, Bryan E Shepherd, Samuel E Stinnette, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Extensively drug-resistant tuberculosis: are we learning from history or repeating it?Carol Dukes Hamilton, Timothy R Sterling, Henry M Blumberg, et al.
American Journal of Respiratory and Critical Care Medicine|November 13, 2019
Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical ModelingJason E Stout, Nicholas A Turner, Robert W Belknap, et al.
The Journal of Infectious Diseases|August 19, 2005
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3Todd Hulgan, Stephen Raffanti, Asghar Kheshti, et al.
BMC Medical Genetics|March 4, 2010
Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosisAlison A Motsinger-Reif, Paulo R Z Antas, Noffisat O Oki, et al.
The Journal of Antimicrobial Chemotherapy|June 5, 2016
A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosisBrandon Eilertson, Fernanda Maruri, Amondrea Blackman, et al.
American Journal of Respiratory and Critical Care Medicine|April 14, 2020
Reply to Swindells <i>et al.</i>: Trials of Tuberculosis-Preventive Therapy in People with HIV InfectionJason E Stout, Nicholas A Turner, Robert W Belknap, et al.
Pageof 33

Showing results (71-80 of 330) with videos related to

Sort By:
Pageof 33
Plos One|April 6, 2016
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, PeruLeonela Villegas, Larissa Otero, Timothy R Sterling, et al.
The Journal of Infectious Diseases|January 6, 2007
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapyTodd Hulgan, Bryan E Shepherd, Stephen P Raffanti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
From Exposure to Disease: Predicting Tuberculosis ProgressionMariana Araújo-Pereira, Rajita Bhavaraju, Mark Hatherill, et al.
Plos One|October 3, 2012
Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in careVlada V Melekhin, Bryan E Shepherd, Samuel E Stinnette, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Extensively drug-resistant tuberculosis: are we learning from history or repeating it?Carol Dukes Hamilton, Timothy R Sterling, Henry M Blumberg, et al.
American Journal of Respiratory and Critical Care Medicine|November 13, 2019
Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical ModelingJason E Stout, Nicholas A Turner, Robert W Belknap, et al.
The Journal of Infectious Diseases|August 19, 2005
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3Todd Hulgan, Stephen Raffanti, Asghar Kheshti, et al.
BMC Medical Genetics|March 4, 2010
Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosisAlison A Motsinger-Reif, Paulo R Z Antas, Noffisat O Oki, et al.
The Journal of Antimicrobial Chemotherapy|June 5, 2016
A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosisBrandon Eilertson, Fernanda Maruri, Amondrea Blackman, et al.
American Journal of Respiratory and Critical Care Medicine|April 14, 2020
Reply to Swindells <i>et al.</i>: Trials of Tuberculosis-Preventive Therapy in People with HIV InfectionJason E Stout, Nicholas A Turner, Robert W Belknap, et al.
Pageof 33